SCHEMBL13828403

SCHEMBL13828403

Cc1nc2ccc(-c3nn(C)c4ncnc(N)c34)cc2o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMPR1B O00238 1/20 0.64
RIPK2 O43353 1/20 0.64
STK16 O75716 1/20 0.64
STK10 O94804 1/20 0.64
MAP4K4 O95819 1/20 0.64
RET P07949 1/20 0.64
PDGFRB P09619 1/20 0.64
FGFR1 P11362 1/20 0.64
PRKCA P17252 1/20 0.64
DCK P27707 1/20 0.64
MAP2K2 P36507 1/20 0.64
FLT3 P36888 1/20 0.64
BMPR1A P36894 1/20 0.64
ACVR1B P36896 1/20 0.64
TGFBR1 P36897 1/20 0.64
CSNK1A1 P48729 1/20 0.64
CSNK1D P48730 1/20 0.64
CSNK1E P49674 1/20 0.64
CLK3 P49761 1/20 0.64
LIMK1 P53667 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16127375 0.86 BMPR1B (0.86) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL19299722 0.81 MTOR (0.74) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL130513 0.78 SRC (0.79) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL19299633 0.78 MTOR (0.58) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL16117323 0.78 BMPR1B (1.00) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL19299479 0.78 MTOR (0.58) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL19299699 0.78 PIK3CD (0.62) BMPR1BRIPK2STK16STK10MAP4K4
SCHEMBL12608270 0.78 PIK3CD (0.73) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL13201507 0.77 PIK3CD (0.65) RETPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL23997199 0.77 SRC (0.73) PIK3CDPIK3CAPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BMPR1B 3913/4885RIPK2 235/4885STK16 377/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BMPR1B 3913/4885RIPK2 235/4885STK16 377/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB BMPR1B 3913/4885RIPK2 235/4885STK16 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.